Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL

What is it about?

Combing therapy that targets both the intrinsic and extrinsic apoptotic pathways to optimize urothelial cancer cell (UCC) death.

Featured Image

Why is it important?

One of the main treatments for UCC is intravesical BCG. This infectious agent causes a non-specific immune response that in part use the tumor necrosis factor related apoptosis inducing ligand (TRIAL) to cause cell death. Some cells are resistant to TRAIL because of deficient Bid signaling to the intrinsic mitochondrial pathway.